Literature DB >> 16108073

Quality of life in refractory ascites: transjugular intrahepatic portal-systemic shunting versus medical therapy.

Mical S Campbell1, Colleen M Brensinger, Arun J Sanyal, Chris Gennings, Florence Wong, Kris V Kowdley, Timothy McCashland, K Rajender Reddy.   

Abstract

Uncontrolled studies suggest that transjugular intrahepatic portal-systemic shunting (TIPS) may improve quality of life in patients with refractory ascites. We hypothesized that any improvement of quality of life in patients with TIPS would be matched in controls due to the competing effects of improved ascites and worsened hepatic encephalopathy. Thus, an analysis of quality of life was performed using original data from the North American Study for the Treatment of Refractory Ascites, a multicenter trial of 109 patients randomized to TIPS or repeated large volume paracentesis (LVP) for refractory ascites. Short form 36 (SF-36) surveys were completed at baseline and at 6- and 12-month follow-up. Variables analyzed were: randomization group, number of LVP performed, cumulative volume from LVP, shortness of breath, abdominal distention, abdominal pain, diuretic usage, confusion, hospitalizations, and emergency room visits. Outcomes were changes in physical component scale (PCS) and mental component scale (MCS) of SF-36 results. We constructed multivariable, mixed effects models, including randomization group and baseline MCS and PCS. Changes in PCS and MCS from baseline were similar between the two randomization groups. In multivariate analysis, PCS improvement was associated with lack of confusion, improved ascites, and lack of hospitalizations, but not directly with randomization group. Improvement in MCS was associated with randomization to TIPS and lack of confusion. In conclusion, patients with refractory ascites randomized to TIPS or repeated LVP had similar changes in quality of life. Competing effects of hepatic encephalopathy, requirement for repeated LVP, and need for hospitalizations explain similar changes in quality of life between the two groups.

Entities:  

Mesh:

Year:  2005        PMID: 16108073     DOI: 10.1002/hep.20840

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

1.  Treatment of refractory ascites.

Authors:  Praveena G Velamati; H Franklin Herlong
Journal:  Curr Treat Options Gastroenterol       Date:  2006

2.  Parallel TIPS for treatment of refractory ascites and hepatic hydrothorax.

Authors:  Ahmad Parvinian; Ron C Gaba
Journal:  Dig Dis Sci       Date:  2013-04-27       Impact factor: 3.199

Review 3.  Evidence-based clinical practice guidelines for liver cirrhosis 2015.

Authors:  Hiroshi Fukui; Hidetsugu Saito; Yoshiyuki Ueno; Hirofumi Uto; Katsutoshi Obara; Isao Sakaida; Akitaka Shibuya; Masataka Seike; Sumiko Nagoshi; Makoto Segawa; Hirohito Tsubouchi; Hisataka Moriwaki; Akinobu Kato; Etsuko Hashimoto; Kojiro Michitaka; Toshikazu Murawaki; Kentaro Sugano; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-05-31       Impact factor: 7.527

4.  Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study.

Authors:  Maria Stepanova; Fatema Nader; Christophe Bureau; Danielle Adebayo; Laure Elkrief; Dominique Valla; Markus Peck-Radosavljevic; Anne McCune; Victor Vargas; Macarena Simon-Talero; Juan Cordoba; Paolo Angeli; Silvia Rossi; Stewart MacDonald; Jeroen Capel; Rajiv Jalan; Zobair M Younossi
Journal:  Qual Life Res       Date:  2018-02-19       Impact factor: 4.147

5.  Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event.

Authors:  Lorenz Balcar; Marta Tonon; Georg Semmler; Valeria Calvino; Lukas Hartl; Simone Incicco; Mathias Jachs; David Bauer; Benedikt Silvester Hofer; Carmine Gabriele Gambino; Antonio Accetta; Alessandra Brocca; Michael Trauner; Mattias Mandorfer; Salvatore Piano; Thomas Reiberger
Journal:  JHEP Rep       Date:  2022-06-03

6.  Development and Validation of a Patient-Reported Outcome Measurement for Symptom Assessment in Cirrhotic Ascites.

Authors:  Myrte Neijenhuis; Tom J G Gevers; Thomas D Atwell; Tim J Gunneson; Amanda C Schimek; Wietske Kievit; Joost P H Drenth; Patrick S Kamath
Journal:  Am J Gastroenterol       Date:  2018-03-20       Impact factor: 10.864

7.  Cirrhotic ascites review: Pathophysiology, diagnosis and management.

Authors:  Christopher M Moore; David H Van Thiel
Journal:  World J Hepatol       Date:  2013-05-27

8.  Treatment for ascites in adults with decompensated liver cirrhosis: a network meta-analysis.

Authors:  Amine Benmassaoud; Suzanne C Freeman; Davide Roccarina; Maria Corina Plaz Torres; Alex J Sutton; Nicola J Cooper; Laura Iogna Prat; Maxine Cowlin; Elisabeth Jane Milne; Neil Hawkins; Brian R Davidson; Chavdar S Pavlov; Douglas Thorburn; Emmanuel Tsochatzis; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2020-01-16

9.  Guidelines on the management of ascites in cirrhosis.

Authors:  Guruprasad P Aithal; Naaventhan Palaniyappan; Louise China; Suvi Härmälä; Lucia Macken; Jennifer M Ryan; Emilie A Wilkes; Kevin Moore; Joanna A Leithead; Peter C Hayes; Alastair J O'Brien; Sumita Verma
Journal:  Gut       Date:  2020-10-16       Impact factor: 23.059

10.  The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension: current status.

Authors:  Gilles Pomier-Layrargues; Louis Bouchard; Michel Lafortune; Julien Bissonnette; Dave Guérette; Pierre Perreault
Journal:  Int J Hepatol       Date:  2012-07-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.